FI934825A0 - 5-arylindol derivat - Google Patents

5-arylindol derivat

Info

Publication number
FI934825A0
FI934825A0 FI934825A FI934825A FI934825A0 FI 934825 A0 FI934825 A0 FI 934825A0 FI 934825 A FI934825 A FI 934825A FI 934825 A FI934825 A FI 934825A FI 934825 A0 FI934825 A0 FI 934825A0
Authority
FI
Finland
Prior art keywords
alkyl
aryl
hydrogen
ring
membered
Prior art date
Application number
FI934825A
Other languages
English (en)
Other versions
FI111257B (fi
FI934825A (fi
Inventor
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI934825A0 publication Critical patent/FI934825A0/fi
Publication of FI934825A publication Critical patent/FI934825A/fi
Application granted granted Critical
Publication of FI111257B publication Critical patent/FI111257B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
FI934825A 1992-11-02 1993-11-01 Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet FI111257B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
US97075892 1992-11-02

Publications (3)

Publication Number Publication Date
FI934825A0 true FI934825A0 (fi) 1993-11-01
FI934825A FI934825A (fi) 1994-05-03
FI111257B FI111257B (fi) 2003-06-30

Family

ID=25517470

Family Applications (2)

Application Number Title Priority Date Filing Date
FI934825A FI111257B (fi) 1992-11-02 1993-11-01 Menetelmä terapeuttisesti käyttökelpoisten 5-aryyli-indolijohdannaisten valmistamiseksi sekä uudet välituoteyhdisteet
FI20002505A FI20002505A (fi) 1992-11-02 2000-11-15 5-aryyli-indolijohdannaisia

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI20002505A FI20002505A (fi) 1992-11-02 2000-11-15 5-aryyli-indolijohdannaisia

Country Status (27)

Country Link
US (1) US5886008A (fi)
EP (2) EP0666858B1 (fi)
JP (1) JP2788551B2 (fi)
KR (1) KR0163371B1 (fi)
CN (1) CN1051313C (fi)
AT (1) ATE202102T1 (fi)
AU (1) AU685066B2 (fi)
BR (1) BR9307348A (fi)
CA (2) CA2148380C (fi)
CZ (1) CZ283001B6 (fi)
DE (1) DE69330351T2 (fi)
DK (1) DK0666858T3 (fi)
EG (1) EG20396A (fi)
ES (1) ES2157224T3 (fi)
FI (2) FI111257B (fi)
GR (1) GR3036579T3 (fi)
HU (1) HU222235B1 (fi)
IL (1) IL107386A (fi)
MY (1) MY109696A (fi)
NO (1) NO309652B1 (fi)
NZ (1) NZ257059A (fi)
PL (1) PL176091B1 (fi)
PT (1) PT666858E (fi)
RU (1) RU2134266C1 (fi)
TW (1) TW251284B (fi)
WO (1) WO1994010171A1 (fi)
ZA (1) ZA938137B (fi)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
US5688809A (en) * 1994-02-10 1997-11-18 Pfizer Inc. 5-heteroarylindole derivatives
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
JPH11502816A (ja) * 1995-03-20 1999-03-09 イーライ・リリー・アンド・カンパニー ５−置換−３−（１，２，３，６−テトラヒドロピリジン−４−イル）−および３−（ピペリジン−４−イル）−１ｈ−インドール類：新規５−ｈｔ▲下１ｆ▼アゴニスト
JPH11513666A (ja) * 1995-10-10 1999-11-24 イーライ・リリー・アンド・カンパニー Ｎ−［２−置換−３−（２−アミノエチル）−１ｈ−インドール−５−イル］−アミド：新規５−ｈｔ▲下１ｆ▼作動剤
CA2294117A1 (en) * 1997-07-03 1999-01-14 Dupont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
CA2334897A1 (en) * 1998-06-30 2000-01-06 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
AU2003284981B2 (en) 2002-10-30 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
EP1620095A4 (en) 2003-04-24 2009-04-01 Merck & Co Inc INHIBITORS OF AKT ACTIVITY
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
SG131944A1 (en) * 2003-08-21 2007-05-28 Osi Pharm Inc N3-substituted imidazopyridine-derivatives as c-kit inhibitors
CA2540541C (en) 2003-10-03 2012-03-27 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2016176460A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Azabenzimidazoles and their use as ampa receptor modulators
EP3288935B1 (en) 2015-04-29 2019-10-30 Janssen Pharmaceutica NV Indolone compounds and their use as ampa receptor modulators
KR20170141768A (ko) 2015-04-29 2017-12-26 얀센 파마슈티카 엔.브이. 이미다조피라진 및 피라졸로피리미딘 및 ampa 수용체 조절제로서의 이의 용도
CA2984290C (en) 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
CN107810002B (zh) 2015-05-22 2021-01-05 艾吉因生物股份有限公司 左乙拉西坦的延时释放药物组合物
EP3371169B1 (en) 2015-11-06 2019-07-17 H. Hoffnabb-La Roche Ag Indolin-2-one derivatives for use in the treatment of cns and related disorders
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN108137555B (zh) 2015-11-06 2021-02-19 豪夫迈·罗氏有限公司 可用于治疗cns疾病的二氢吲哚-2-酮衍生物
AU2016348493B2 (en) 2015-11-06 2021-02-25 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
ZA815541B (en) * 1980-08-12 1983-03-30 Glaxo Group Ltd Heterocyclic compounds
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8724912D0 (en) * 1987-10-23 1987-11-25 Wellcome Found Indole derivatives
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
SI21560B (sl) * 1990-06-07 2005-04-30 Astrazeneca Ab 3,5-disubstituirani indolni derivati kot "5-HT1-podobni" receptorski agonisti
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
CZ283018B6 (cs) * 1991-02-01 1997-12-17 Merck Sharp And Dohme Limited Deriváty imidazolu, triazolu a tetrazolu a farmaceutické přípravky na jejich bázi
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Also Published As

Publication number Publication date
AU685066B2 (en) 1998-01-15
DE69330351D1 (de) 2001-07-19
AU5329494A (en) 1994-05-24
EP0666858A1 (en) 1995-08-16
JP2788551B2 (ja) 1998-08-20
NO951633D0 (no) 1995-04-28
CA2148380A1 (en) 1994-05-11
KR0163371B1 (ko) 1998-12-01
ES2157224T3 (es) 2001-08-16
PL308669A1 (en) 1995-08-21
KR950704313A (ko) 1995-11-17
DE69330351T2 (de) 2001-09-20
GR3036579T3 (en) 2001-12-31
ATE202102T1 (de) 2001-06-15
IL107386A (en) 1999-03-12
CA2340999C (en) 2005-01-04
IL107386A0 (en) 1994-01-25
EP1094064A1 (en) 2001-04-25
CA2148380C (en) 2001-08-14
CA2340999A1 (en) 1994-05-11
FI111257B (fi) 2003-06-30
JPH07508759A (ja) 1995-09-28
ZA938137B (en) 1995-05-02
RU95109927A (ru) 1997-01-10
EP0666858B1 (en) 2001-06-13
CZ110895A3 (en) 1995-11-15
CN1051313C (zh) 2000-04-12
WO1994010171A1 (en) 1994-05-11
CZ283001B6 (cs) 1997-12-17
EG20396A (en) 1999-02-28
NZ257059A (en) 1997-07-27
NO309652B1 (no) 2001-03-05
RU2134266C1 (ru) 1999-08-10
FI20002505A (fi) 2000-11-15
MY109696A (en) 1997-04-30
BR9307348A (pt) 1999-05-11
CN1094727A (zh) 1994-11-09
PT666858E (pt) 2001-09-28
DK0666858T3 (da) 2001-08-27
HUT66011A (en) 1994-08-29
PL176091B1 (pl) 1999-04-30
NO951633L (no) 1995-04-28
HU222235B1 (hu) 2003-05-28
FI934825A (fi) 1994-05-03
TW251284B (fi) 1995-07-11
US5886008A (en) 1999-03-23

Similar Documents

Publication Publication Date Title
FI934825A (fi) 5-arylindol derivat
ES2123873T3 (es) Pirrolocarbazol.
DE69810373D1 (de) Pyrrolidin Derivate, Anti-ulcus und Antibakterielle Arzneimittel
ATE160562T1 (de) Piperazinderivate
ATE134607T1 (de) Tetrahydronaphtalenderivate, ihre herstellung und ihre therapeutische verwendung
ES2077697T3 (es) Derivados de 1-fenoxicarbonil-2-pirrolidinona y agentes nootropicos.

Legal Events

Date Code Title Description
FD Application lapsed
MA Patent expired